Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BrYet Health
Houston, Texas, United Statesbryetpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Preclinical studies demonstrated unprecedented efficacy, with ~50% long-term survival in otherwise uniformly lethal metastatic models. First-in-human Phase 1/2 trial of ML-016 (amino acid polymer-doxorubicin conjugate with mesoporous silicon carriers) in patients with advanced metastatic cancers involving lung or liver starts in 2026. Initial human data pending.
- Therapeutic areas
- Oncology
- Modalities
- Polymer-drug conjugate therapySmall molecule
- Industry
- Biotech
02
Partnerships
NerPharMa (manufacturing partner)
Beyond the preview
Go deeper on BrYet Health.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BrYet Health.